BOULDER, Colo., April 26, 2016 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2016 and hold a conference call to discuss those results on Tuesday, May 3, 2016. Ron Squarer, Chief Executive Officer, will lead the call.

http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO



    Date:                          Tuesday, May 3, 2016

    Time:                          9:00 a.m. Eastern Time

    Toll-Free:                     (844) 464-3927

    Toll:                          (765) 507-2598

    Pass Code:                                            86078064

    Webcast, including Replay and Conference Call Slides:
    http://edge.media-server.com/m/p/stxvbem8

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Five registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162), encorafenib (LGX818) and selumetinib (AstraZeneca). For more information on Array, please go to www.arraybiopharma.com.



    CONTACT:                        Tricia Haugeto

                                    Array BioPharma Inc.

                                    (303) 386-1193

                                    thaugeto@arraybiopharma.com

Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2016-on-may-3-2016-300257649.html

SOURCE Array BioPharma Inc.